BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
Completed · Phase 2 · Has a placebo group
Conditions studied: Alzheimer Disease
In brief
The study is designed to compare the effects of BI 409306 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease
Key facts
- Study ID
- NCT02337907
- Run by
- Boehringer Ingelheim
- People needed
- 329
- Starts
- 2015-01-21
- Expected to finish
- 2017-10-10
- Last updated by the study team
- 2018-11-14
Who can join
Age: 55 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with early signs of dementia of Alzheimer Type
- Male and female patients with an age of at least 55 years
- Previous use of Alzheimer's Disease (AD) medications (AChEIs, memantine) is allowed up 3 month prior to screening. Patients who are currently taking AChEIs are eligible as long as they have been using a stable dose for at least 3 months prior to screening and no change is foreseen for the duration of the study. This dose must be consistent with the product label in the concerned country. Patients currently taking memantine are excluded.
- Patients must have at least 6 years of formal education and fluency in the test language as verbally confirmed by the patient and documented by the study investigator.
- Patients must have a reliable study partner (per investigator judgement, for instance a family member, partner etc., guardian or, if applicable, a legal representative)
You may not qualify if…
- Cognitive impairment or dementia with any etiology other than Alzheimer's Disease (AD)
- Substantial concomitant cerebrovascular disease (defined by a history of a stroke / intracranial haemorrhagia) temporally related to the onset of worsening of cognitive impairment per investigator judgement
- Medical history or diagnosis of any of symptomatic and unstable/uncontrolled conditions per investigator judgement
- Any other psychiatric disorders such as schizophrenia, or mental retardation
- Previous participation in investigational drug studies of mild cognitive impairment/Dementia of Alzheimer Type (DAT) within three months prior to screening. Having received active treatment in any other study targeting disease modification of AD like Aß immunization and tau therapies. Previous participation in studies with non-prescription medications, vitamins or other nutritional formulations is allowed.
- Clinically significant uncompensated hearing loss in the judgment of the investigator. Use of hearing aids is allowed.
Where it is running
- Bioclinica Research — Orlando, Florida, United States
- Premiere Research Institute — West Palm Beach, Florida, United States
- Indiana University — Indianapolis, Indiana, United States
- Memory Enhancement Center of America, Inc. — Eatontown, New Jersey, United States
- Psychiatry And Alzheimer's Care of Rochester, PLLC — Rochester, New York, United States
- Richmond Behavioral Associates — Staten Island, New York, United States
- ANI Neurology, PLLC, dba Alzheimer's Memory Center — Charlotte, North Carolina, United States
- Tulsa Clinical Research, LLC — Tulsa, Oklahoma, United States
- The Memory Clinic — Bennington, Vermont, United States
- Private Practice for Psychiatry and Neurology — Vienna, Austria
- Brussels-UNIV Brugmann -Horta — Brussels, Belgium
- AZ Sint-Blasius — Dendermonde, Belgium
- UNIV UZ Gent — Ghent, Belgium
- Mons - UNIV Ambroise Paré — Mons, Belgium
- University of Calgary — Calgary, Alberta, Canada
- Dr. Alexander McIntyre Inc. — Penticton, British Columbia, Canada
- Pasqua Hospital — Regina, Saskatchewan, Canada
- Institut universitaire de geriatrie Sherbrooke — Québec, Canada
- HOP Pellegrin — Bordeaux, France
- HOP Bocage — Dijon, France
- HOP Timone — Marseille, France
- HOP Gui de Chauliac — Montpellier, France
- HOP Nord Laënnec — Nantes, France
- HOP La Pitié Salpêtrière — Paris, France
- California Neuroscience Research — Sherman Oaks, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.